Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German chronic lymphocytic leukemia study group

Journal of Clinical Oncology

Volumn 27, Issue 24, 2009, Pages 3994-4001

  Stilgenbauer, Stephan ^a   Zenz, Thorsten ^a   Winkler, Dirk ^a   Bühler, Andreas ^a   Schlenk, Richard F ^a   Groner, Silja ^a   Busch, Raymonde ^a   Hensel, Manfred ^a   Dührsen, Ulrich ^a   Finke, Jürgen ^a   Dreger, Peter ^a   Jäger, Ulrich ^a   Lengfelder, Eva ^a   Hohloch, Karin ^a   Söling, Ulrike ^a   Schlag, Rudolf ^a   Kneba, Michael ^a   Hallek, Michael ^a   Döhner, Hartmut ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; BETA 2 MICROGLOBULIN; CORTICOSTEROID; COTRIMOXAZOLE; DRUG ANTIBODY; FAMCICLOVIR; FLUDARABINE; LACTATE DEHYDROGENASE; PROTEIN; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; VH PROTEIN; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENETIC PARAMETERS; HERPES SIMPLEX; HUMAN; INFECTION; INJECTION SITE REACTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; VIDARABINE;

EID: 69849107362     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.1128     Document Type: Article

References (41)

1. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230-239, 2007
2. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006
3. Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-798, 2007
4. Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25, 1989
5. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005
6. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
7. Keating MJ, O'Brien S, Kontoyiannis D, et al: Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 43:1755-1762, 2002
8. Demko S, Summers J, Keegan P, et al: FDA drug approval summary: Alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 13:167-174, 2008
9. Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623, 2007
10. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99:3554-3561, 2002
11. Bayer HealthCare Pharmaceuticals. Campath Prescription Information. Bayer Schering Pharma, 2007
12. Hale G, Rebello P, Brettman LR, et al: Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104:948-955, 2004
13. Karlsson C, Norin S, Kimby E, et al: Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: Long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 20:2204-2207, 2006
14. Lundin J, Kimby E, Bjorkholm M, et al: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768-773, 2002
15. Kay NE, O'Brien SM, Pettitt AR, et al: The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 21:1885-1891, 2007
16. Döhner H, Fischer K, Bentz M, et al: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589, 1995
17. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
18. Grever MR, Lucas DM, Dewald GW, et al: Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25: 799-804, 2007
19. Lozanski G, Heerema NA, Flinn IW, et al: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278-3281, 2004
20. Osuji NC, Del GI, Matutes E, et al: The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 90:1435-1436, 2005
21. Stilgenbauer S, Döhner H: Campath-1Hinduced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347:452-453, 2002
22. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
23. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255-260, 1986
24. Cox DR: Regression models and life-tables. J R Stat Soc 34:187-220, 1972
25. Harrell FE: Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Springer Verlag, 2001
26. Lausen B, Schumacher M: Maximally selected rank statistics. Biometrics 48:73-85, 1992
27. R Development Core Team: R: A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing, 2007
28. Hallek M, Langenmayer I, Nerl C, et al: Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 93:1732-1737, 1999
29. Kröber A, Seiler T, Benner A, et al: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia Blood 100:1410-1416, 2002
30. Zenz T, Kröber A, Scherer K, et al: Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up. Blood 112:3322-3329, 2008
31. Clarke AR, Purdie CA, Harrison DJ, et al: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993
32. Pettitt AR, Matutes E, Oscier D: Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 20:1441-1445, 2006
33. Byrd JC, Lin TS, Dalton JT, et al: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399-404, 2007
34. Chanan-Khan A, Miller KC, Musial L, et al: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 24:5343-5349, 2006
35. Ferrajoli A, Lee BN, Schlette EJ, et al: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291-5297, 2008
36. Moreno C, Villamor N, Colomer D, et al: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23:3433-3438, 2005
37. Ritgen M, Stilgenbauer S, von Neuhoff N, et al: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavychain gene status: Implications of minimal residual disease measurement with quantitative PCR. Blood 104:2600-2602, 2004
38. Schetelig J, Thiede C, Bornhauser M, et al: Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group. J Clin Oncol 21:2747-2753, 2003
39. Sorror ML, Maris MB, Sandmaier BM, et al: Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23:3819-3829, 2005
40. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
41. Schetelig J, van BA, Brand R, et al: Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: A retrospective European group for blood and marrow transplantation analysis. J Clin Oncol 26:5094-5100, 2008